Positive Safety Results For Dendreon's Prostate Drug By: MarketMinute.com Stock News April 14, 2009 at 14:00 PM EDT Shares of Dendreon Corp. (Nasdaq: DNDN) rocketed $10.21 to $17.51 after the biotechnology company announced positive safety results for its prostate cancer drug treatment.